Candel Therapeutics Revenue
Biotechnology Research • 
Needham, Massachusetts, United States • 51-100 Employees
Candel Therapeutics revenue & valuation
| Annual revenue | $125,000 |
| Revenue per employee | $2,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $400,000 |
| Total funding | $132,000,000 |
Key Contacts at Candel Therapeutics
Mayank Rao Md
Senior Medical Director
Todd Lefurge
Director, Clinical Data Management
Brian Egan
Senior Director Of Pharmacovigilance And Safety
Shangbang Rao
Senior Director, Biostatistics
Kristen Baslee Smith
Director Clinical Operations Quality
John Cox
Director Supply Chain
Foster Malcolm
Director, Gxp Project Management
Douglas Lane
Associate Director, Regulatory Affairs
Allison Nylen
Director Of Finance
Estuardo Aguilar-Cordova
Founder And Director
Company overview
| Headquarters | 117 Kendrick Street, Suite 450, Needham, Massachusetts 02494, US |
| Phone number | +16179165445 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biotechnology, Prostate Cancer, Oncology, Immuno-Oncology, Brain Cancer, Viral Immunotherapy |
| Founded | 1999 |
| Employees | 51-100 |
| Socials |
Candel Therapeutics Email Formats
Candel Therapeutics uses 4 email formats. The most common is {first initial}{last name} (e.g., jdoe@candeltx.com), used 53.1% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@candeltx.com | 53.1% |
{first name}{last name} | johndoe@candeltx.com | 42.9% |
{first initial} | j@candeltx.com | 2% |
{last name}{last name} | doedoe@candeltx.com | 2% |
About Candel Therapeutics
Candel ($CADL) is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). In addition, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). For more information, visit www.candeltx.com or contact us at info@candeltx.com.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Candel Therapeutics has 35 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Candel Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Candel Therapeutics Tech Stack
Discover the technologies and tools that power Candel Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Video players
JavaScript libraries
Issue trackers
Video players
Miscellaneous
JavaScript libraries
JavaScript libraries
JavaScript libraries
CDN
Font scripts
JavaScript libraries
Canada
United Kingdom
Israel
Australia
Norway
SwitzerlandFrequently asked questions
4.8
40,000 users
